#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4.
1-1	0-2	4.	_	_	_	_

#Text=Discussion
2-1	3-13	Discussion	abstract	new	_	_

#Text=We found bilateral hypersensitivity to pressure pain within the temporalis muscle in men with episodic CH not to be associated with levels of anxiety or depression .
3-1	14-16	We	person	acc	ana	4-3
3-2	17-22	found	_	_	_	_
3-3	23-32	bilateral	abstract[3]	new[3]	coref	6-9[33_3]
3-4	33-49	hypersensitivity	abstract[3]	new[3]	_	_
3-5	50-52	to	abstract[3]	new[3]	_	_
3-6	53-61	pressure	abstract[3]|abstract|abstract[5]	new[3]|new|new[5]	coref|coref	4-13|4-13[17_5]
3-7	62-66	pain	abstract[3]|abstract[5]	new[3]|new[5]	_	_
3-8	67-73	within	abstract[3]|abstract[5]	new[3]|new[5]	_	_
3-9	74-77	the	abstract[3]|abstract[5]|object[6]	new[3]|new[5]|new[6]	coref	10-8[64_6]
3-10	78-88	temporalis	abstract[3]|abstract[5]|object[6]	new[3]|new[5]|new[6]	_	_
3-11	89-95	muscle	abstract[3]|abstract[5]|object[6]	new[3]|new[5]|new[6]	_	_
3-12	96-98	in	_	_	_	_
3-13	99-102	men	person[7]	new[7]	coref	4-16[18_7]
3-14	103-107	with	person[7]	new[7]	_	_
3-15	108-116	episodic	person[7]|abstract[8]	new[7]|new[8]	coref	4-18[0_8]
3-16	117-119	CH	person[7]|abstract[8]	new[7]|new[8]	_	_
3-17	120-123	not	_	_	_	_
3-18	124-126	to	_	_	_	_
3-19	127-129	be	_	_	_	_
3-20	130-140	associated	_	_	_	_
3-21	141-145	with	_	_	_	_
3-22	146-152	levels	abstract[9]	new[9]	_	_
3-23	153-155	of	abstract[9]	new[9]	_	_
3-24	156-163	anxiety	abstract[9]|abstract	new[9]|new	_	_
3-25	164-166	or	abstract[9]	new[9]	_	_
3-26	167-177	depression	abstract[9]|abstract	new[9]|new	_	_
3-27	178-179	.	_	_	_	_

#Text=Additionally , our mapping revealed a spatial anterior-to-posterior gradient of sensitivity to pressure pain in men with CH but not in headache-free controls .
4-1	180-192	Additionally	_	_	_	_
4-2	193-194	,	_	_	_	_
4-3	195-198	our	person|abstract[13]	giv|new[13]	ana|coref	5-4|17-1[113_13]
4-4	199-206	mapping	abstract[13]	new[13]	_	_
4-5	207-215	revealed	_	_	_	_
4-6	216-217	a	abstract[14]	new[14]	_	_
4-7	218-225	spatial	abstract[14]	new[14]	_	_
4-8	226-247	anterior-to-posterior	abstract[14]	new[14]	_	_
4-9	248-256	gradient	abstract[14]	new[14]	_	_
4-10	257-259	of	abstract[14]	new[14]	_	_
4-11	260-271	sensitivity	abstract[14]|abstract[15]	new[14]|new[15]	coref	17-1[112_15]
4-12	272-274	to	abstract[14]|abstract[15]	new[14]|new[15]	_	_
4-13	275-283	pressure	abstract[14]|abstract[15]|abstract|abstract[17]	new[14]|new[15]|giv|giv[17]	coref|coref	6-12[0_17]|6-12[35_0]
4-14	284-288	pain	abstract[14]|abstract[15]|abstract[17]	new[14]|new[15]|giv[17]	_	_
4-15	289-291	in	_	_	_	_
4-16	292-295	men	person[18]	giv[18]	coref	5-15[25_18]
4-17	296-300	with	person[18]	giv[18]	_	_
4-18	301-303	CH	person[18]|abstract	giv[18]|giv	coref	5-17
4-19	304-307	but	_	_	_	_
4-20	308-311	not	_	_	_	_
4-21	312-314	in	_	_	_	_
4-22	315-328	headache-free	abstract[20]	new[20]	coref	5-20[27_20]
4-23	329-337	controls	abstract[20]	new[20]	_	_
4-24	338-339	.	_	_	_	_

#Text=In line with our hypothesis , there was a bilateral decrease of PPTs in men with CH compared with controls with large effect sizes .
5-1	340-342	In	_	_	_	_
5-2	343-347	line	_	_	_	_
5-3	348-352	with	_	_	_	_
5-4	353-356	our	person|abstract[22]	giv|new[22]	ana	6-1
5-5	357-367	hypothesis	abstract[22]	new[22]	_	_
5-6	368-369	,	_	_	_	_
5-7	370-375	there	_	_	_	_
5-8	376-379	was	_	_	_	_
5-9	380-381	a	event[23]	new[23]	_	_
5-10	382-391	bilateral	event[23]	new[23]	_	_
5-11	392-400	decrease	event[23]	new[23]	_	_
5-12	401-403	of	event[23]	new[23]	_	_
5-13	404-408	PPTs	event[23]|abstract	new[23]|new	coref	16-15
5-14	409-411	in	event[23]	new[23]	_	_
5-15	412-415	men	event[23]|person[25]	new[23]|giv[25]	_	_
5-16	416-420	with	event[23]|person[25]	new[23]|giv[25]	_	_
5-17	421-423	CH	event[23]|person[25]|abstract	new[23]|giv[25]|giv	ana	6-5[32_0]
5-18	424-432	compared	_	_	_	_
5-19	433-437	with	_	_	_	_
5-20	438-446	controls	abstract[27]	giv[27]	coref	20-7[139_27]
5-21	447-451	with	abstract[27]	giv[27]	_	_
5-22	452-457	large	abstract[27]|abstract[29]	giv[27]|new[29]	_	_
5-23	458-464	effect	abstract[27]|abstract|abstract[29]	giv[27]|new|new[29]	_	_
5-24	465-470	sizes	abstract[27]|abstract[29]	giv[27]|new[29]	_	_
5-25	471-472	.	_	_	_	_

#Text=Our results agree with those previously reported where bilateral hypersensitivity to pain pressure in the temporalis area in patients with CH was also observed .
6-1	473-476	Our	person|abstract[31]	giv|new[31]	coref|ana	7-3[39_31]|11-1
6-2	477-484	results	abstract[31]	new[31]	_	_
6-3	485-490	agree	_	_	_	_
6-4	491-495	with	_	_	_	_
6-5	496-501	those	abstract[32]	giv[32]	coref	6-21[0_32]
6-6	502-512	previously	abstract[32]	giv[32]	_	_
6-7	513-521	reported	abstract[32]	giv[32]	_	_
6-8	522-527	where	abstract[32]	giv[32]	_	_
6-9	528-537	bilateral	abstract[32]|abstract[33]	giv[32]|giv[33]	coref	10-24[67_33]
6-10	538-554	hypersensitivity	abstract[32]|abstract[33]	giv[32]|giv[33]	_	_
6-11	555-557	to	abstract[32]|abstract[33]	giv[32]|giv[33]	_	_
6-12	558-562	pain	abstract[32]|abstract[33]|abstract|abstract[35]	giv[32]|giv[33]|giv|giv[35]	coref|coref	8-13|9-8[0_35]
6-13	563-571	pressure	abstract[32]|abstract[33]|abstract[35]	giv[32]|giv[33]|giv[35]	_	_
6-14	572-574	in	abstract[32]|abstract[33]|abstract[35]	giv[32]|giv[33]|giv[35]	_	_
6-15	575-578	the	abstract[32]|abstract[33]|abstract[35]|place[36]	giv[32]|giv[33]|giv[35]|new[36]	coref	12-7[79_36]
6-16	579-589	temporalis	abstract[32]|abstract[33]|abstract[35]|place[36]	giv[32]|giv[33]|giv[35]|new[36]	_	_
6-17	590-594	area	abstract[32]|abstract[33]|abstract[35]|place[36]	giv[32]|giv[33]|giv[35]|new[36]	_	_
6-18	595-597	in	abstract[32]|abstract[33]|abstract[35]|place[36]	giv[32]|giv[33]|giv[35]|new[36]	_	_
6-19	598-606	patients	abstract[32]|abstract[33]|abstract[35]|place[36]|person[37]	giv[32]|giv[33]|giv[35]|new[36]|new[37]	coref	7-32[44_37]
6-20	607-611	with	abstract[32]|abstract[33]|abstract[35]|place[36]|person[37]	giv[32]|giv[33]|giv[35]|new[36]|new[37]	_	_
6-21	612-614	CH	abstract[32]|abstract[33]|abstract[35]|place[36]|person[37]|abstract	giv[32]|giv[33]|giv[35]|new[36]|new[37]|giv	coref	7-34
6-22	615-618	was	abstract[32]	giv[32]	_	_
6-23	619-623	also	abstract[32]	giv[32]	_	_
6-24	624-632	observed	abstract[32]	giv[32]	_	_
6-25	633-634	.	_	_	_	_

#Text=However , these results differ from those reported by Malo-Urriés et al. , who observed that the symptomatic side was more sensitive than the non-symptomatic side in a small sample of patients with CH .
7-1	635-642	However	_	_	_	_
7-2	643-644	,	_	_	_	_
7-3	645-650	these	abstract[39]	giv[39]	coref	21-1[142_39]
7-4	651-658	results	abstract[39]	giv[39]	_	_
7-5	659-665	differ	_	_	_	_
7-6	666-670	from	_	_	_	_
7-7	671-676	those	_	_	_	_
7-8	677-685	reported	_	_	_	_
7-9	686-688	by	_	_	_	_
7-10	689-700	Malo-Urriés	person	new	_	_
7-11	701-703	et	_	_	_	_
7-12	704-707	al.	_	_	_	_
7-13	708-709	,	_	_	_	_
7-14	710-713	who	_	_	_	_
7-15	714-722	observed	_	_	_	_
7-16	723-727	that	_	_	_	_
7-17	728-731	the	abstract[41]	new[41]	_	_
7-18	732-743	symptomatic	abstract[41]	new[41]	_	_
7-19	744-748	side	abstract[41]	new[41]	_	_
7-20	749-752	was	_	_	_	_
7-21	753-757	more	_	_	_	_
7-22	758-767	sensitive	_	_	_	_
7-23	768-772	than	_	_	_	_
7-24	773-776	the	abstract[42]	new[42]	_	_
7-25	777-792	non-symptomatic	abstract[42]	new[42]	_	_
7-26	793-797	side	abstract[42]	new[42]	_	_
7-27	798-800	in	_	_	_	_
7-28	801-802	a	animal[43]	new[43]	_	_
7-29	803-808	small	animal[43]	new[43]	_	_
7-30	809-815	sample	animal[43]	new[43]	_	_
7-31	816-818	of	animal[43]	new[43]	_	_
7-32	819-827	patients	animal[43]|person[44]	new[43]|giv[44]	coref	8-16[52_44]
7-33	828-832	with	animal[43]|person[44]	new[43]|giv[44]	_	_
7-34	833-835	CH	animal[43]|person[44]|abstract	new[43]|giv[44]|giv	coref	8-16
7-35	836-837	.	_	_	_	_

#Text=The current and previous findings suggest the presence of sensitization of trigeminal pain pathways in CH patients .
8-1	838-841	The	abstract[46]	new[46]	coref	13-1[83_46]
8-2	842-849	current	abstract[46]	new[46]	_	_
8-3	850-853	and	abstract[46]	new[46]	_	_
8-4	854-862	previous	abstract[46]	new[46]	_	_
8-5	863-871	findings	abstract[46]	new[46]	_	_
8-6	872-879	suggest	_	_	_	_
8-7	880-883	the	abstract[47]	new[47]	_	_
8-8	884-892	presence	abstract[47]	new[47]	_	_
8-9	893-895	of	abstract[47]	new[47]	_	_
8-10	896-909	sensitization	abstract[47]|abstract[48]	new[47]|new[48]	_	_
8-11	910-912	of	abstract[47]|abstract[48]	new[47]|new[48]	_	_
8-12	913-923	trigeminal	abstract[47]|abstract[48]|abstract[50]	new[47]|new[48]|new[50]	coref	24-5[155_50]
8-13	924-928	pain	abstract[47]|abstract[48]|abstract|abstract[50]	new[47]|new[48]|giv|new[50]	coref	9-9
8-14	929-937	pathways	abstract[47]|abstract[48]|abstract[50]	new[47]|new[48]|new[50]	_	_
8-15	938-940	in	abstract[47]|abstract[48]	new[47]|new[48]	_	_
8-16	941-943	CH	abstract[47]|abstract[48]|abstract|person[52]	new[47]|new[48]|giv|giv[52]	coref|coref	9-12[57_52]|12-17
8-17	944-952	patients	abstract[47]|abstract[48]|person[52]	new[47]|new[48]|giv[52]	_	_
8-18	953-954	.	_	_	_	_

#Text=In addition , the presence of bilateral pressure pain hyperalgesia in patients with unilateral symptoms supports potential sensitization of the central nervous system , as previously suggested , although further studies are needed .
9-1	955-957	In	_	_	_	_
9-2	958-966	addition	_	_	_	_
9-3	967-968	,	_	_	_	_
9-4	969-972	the	abstract[53]	new[53]	_	_
9-5	973-981	presence	abstract[53]	new[53]	_	_
9-6	982-984	of	abstract[53]	new[53]	_	_
9-7	985-994	bilateral	abstract[53]|abstract[56]	new[53]|new[56]	coref	10-3[62_56]
9-8	995-1003	pressure	abstract[53]|abstract|abstract[56]	new[53]|giv|new[56]	coref	10-6[63_0]
9-9	1004-1008	pain	abstract[53]|abstract|abstract[56]	new[53]|giv|new[56]	coref	12-4
9-10	1009-1021	hyperalgesia	abstract[53]|abstract[56]	new[53]|new[56]	_	_
9-11	1022-1024	in	abstract[53]	new[53]	_	_
9-12	1025-1033	patients	abstract[53]|person[57]	new[53]|giv[57]	coref	10-16[65_57]
9-13	1034-1038	with	abstract[53]|person[57]	new[53]|giv[57]	_	_
9-14	1039-1049	unilateral	abstract[53]|person[57]|abstract[58]	new[53]|giv[57]|new[58]	coref	10-32[69_58]
9-15	1050-1058	symptoms	abstract[53]|person[57]|abstract[58]	new[53]|giv[57]|new[58]	_	_
9-16	1059-1067	supports	_	_	_	_
9-17	1068-1077	potential	abstract[59]	new[59]	coref	13-11[85_59]
9-18	1078-1091	sensitization	abstract[59]	new[59]	_	_
9-19	1092-1094	of	abstract[59]	new[59]	_	_
9-20	1095-1098	the	abstract[59]|abstract[60]	new[59]|new[60]	_	_
9-21	1099-1106	central	abstract[59]|abstract[60]	new[59]|new[60]	_	_
9-22	1107-1114	nervous	abstract[59]|abstract[60]	new[59]|new[60]	_	_
9-23	1115-1121	system	abstract[59]|abstract[60]	new[59]|new[60]	_	_
9-24	1122-1123	,	_	_	_	_
9-25	1124-1126	as	_	_	_	_
9-26	1127-1137	previously	_	_	_	_
9-27	1138-1147	suggested	_	_	_	_
9-28	1148-1149	,	_	_	_	_
9-29	1150-1158	although	_	_	_	_
9-30	1159-1166	further	abstract[61]	new[61]	coref	25-36[174_61]
9-31	1167-1174	studies	abstract[61]	new[61]	_	_
9-32	1175-1178	are	_	_	_	_
9-33	1179-1185	needed	_	_	_	_
9-34	1186-1187	.	_	_	_	_

#Text=Similarly , bilateral hyperalgesia to pressure over the temporalis muscle has previously been found in patients with strictly unilateral migraine , suggesting that bilateral hypersensitivity is present albeit the presence of just unilateral symptoms in individuals with primary headaches .
10-1	1188-1197	Similarly	_	_	_	_
10-2	1198-1199	,	_	_	_	_
10-3	1200-1209	bilateral	abstract[62]	giv[62]	coref	12-3[78_62]
10-4	1210-1222	hyperalgesia	abstract[62]	giv[62]	_	_
10-5	1223-1225	to	abstract[62]	giv[62]	_	_
10-6	1226-1234	pressure	abstract[62]|abstract[63]	giv[62]|giv[63]	coref	12-3[0_63]
10-7	1235-1239	over	abstract[62]|abstract[63]	giv[62]|giv[63]	_	_
10-8	1240-1243	the	abstract[62]|abstract[63]|object[64]	giv[62]|giv[63]|giv[64]	coref	19-18[133_64]
10-9	1244-1254	temporalis	abstract[62]|abstract[63]|object[64]	giv[62]|giv[63]|giv[64]	_	_
10-10	1255-1261	muscle	abstract[62]|abstract[63]|object[64]	giv[62]|giv[63]|giv[64]	_	_
10-11	1262-1265	has	_	_	_	_
10-12	1266-1276	previously	_	_	_	_
10-13	1277-1281	been	_	_	_	_
10-14	1282-1287	found	_	_	_	_
10-15	1288-1290	in	_	_	_	_
10-16	1291-1299	patients	person[65]	giv[65]	coref	11-1[73_65]
10-17	1300-1304	with	person[65]	giv[65]	_	_
10-18	1305-1313	strictly	person[65]|event[66]	giv[65]|new[66]	coref	21-22[148_66]
10-19	1314-1324	unilateral	person[65]|event[66]	giv[65]|new[66]	_	_
10-20	1325-1333	migraine	person[65]|event[66]	giv[65]|new[66]	_	_
10-21	1334-1335	,	_	_	_	_
10-22	1336-1346	suggesting	_	_	_	_
10-23	1347-1351	that	_	_	_	_
10-24	1352-1361	bilateral	abstract[67]	giv[67]	_	_
10-25	1362-1378	hypersensitivity	abstract[67]	giv[67]	_	_
10-26	1379-1381	is	_	_	_	_
10-27	1382-1389	present	_	_	_	_
10-28	1390-1396	albeit	_	_	_	_
10-29	1397-1400	the	abstract[68]	new[68]	_	_
10-30	1401-1409	presence	abstract[68]	new[68]	_	_
10-31	1410-1412	of	abstract[68]	new[68]	_	_
10-32	1413-1417	just	abstract[68]|abstract[69]	new[68]|giv[69]	coref	24-29[162_69]
10-33	1418-1428	unilateral	abstract[68]|abstract[69]	new[68]|giv[69]	_	_
10-34	1429-1437	symptoms	abstract[68]|abstract[69]	new[68]|giv[69]	_	_
10-35	1438-1440	in	abstract[68]	new[68]	_	_
10-36	1441-1452	individuals	abstract[68]|person[70]	new[68]|new[70]	coref	29-26[211_70]
10-37	1453-1457	with	abstract[68]|person[70]	new[68]|new[70]	_	_
10-38	1458-1465	primary	abstract[68]|person[70]|abstract[71]	new[68]|new[70]|new[71]	coref	15-16[101_71]
10-39	1466-1475	headaches	abstract[68]|person[70]|abstract[71]	new[68]|new[70]|new[71]	_	_
10-40	1476-1477	.	_	_	_	_

#Text=Our patients were assessed during a long-lasting remission phase .
11-1	1478-1481	Our	person|person[73]	giv|giv[73]	coref|ana	12-15[80_73]|16-3
11-2	1482-1490	patients	person[73]	giv[73]	_	_
11-3	1491-1495	were	_	_	_	_
11-4	1496-1504	assessed	_	_	_	_
11-5	1505-1511	during	_	_	_	_
11-6	1512-1513	a	abstract[75]	new[75]	coref	14-33[97_75]
11-7	1514-1526	long-lasting	abstract[75]	new[75]	_	_
11-8	1527-1536	remission	event|abstract[75]	new|new[75]	coref	14-34
11-9	1537-1542	phase	abstract[75]	new[75]	_	_
11-10	1543-1544	.	_	_	_	_

#Text=Therefore , pressure pain hyperalgesia in the trigeminal area seems to be present in patients with CH during asymptomatic periods .
12-1	1545-1554	Therefore	_	_	_	_
12-2	1555-1556	,	_	_	_	_
12-3	1557-1565	pressure	abstract|abstract[78]	giv|giv[78]	coref|coref	18-10|26-22[182_78]
12-4	1566-1570	pain	abstract|abstract[78]	giv|giv[78]	coref	13-19
12-5	1571-1583	hyperalgesia	abstract[78]	giv[78]	_	_
12-6	1584-1586	in	abstract[78]	giv[78]	_	_
12-7	1587-1590	the	abstract[78]|place[79]	giv[78]|giv[79]	coref	19-30[136_79]
12-8	1591-1601	trigeminal	abstract[78]|place[79]	giv[78]|giv[79]	_	_
12-9	1602-1606	area	abstract[78]|place[79]	giv[78]|giv[79]	_	_
12-10	1607-1612	seems	_	_	_	_
12-11	1613-1615	to	_	_	_	_
12-12	1616-1618	be	_	_	_	_
12-13	1619-1626	present	_	_	_	_
12-14	1627-1629	in	_	_	_	_
12-15	1630-1638	patients	person[80]	giv[80]	coref	18-15[125_80]
12-16	1639-1643	with	person[80]	giv[80]	_	_
12-17	1644-1646	CH	person[80]|abstract	giv[80]|giv	coref	13-14
12-18	1647-1653	during	_	_	_	_
12-19	1654-1666	asymptomatic	time[82]	new[82]	coref	13-17[87_82]
12-20	1667-1674	periods	time[82]	new[82]	_	_
12-21	1675-1676	.	_	_	_	_

#Text=These findings indicate that there is a baseline state of trigeminal sensitization in CH predisposing to periods of pain .
13-1	1677-1682	These	abstract[83]	giv[83]	coref	19-3[128_83]
13-2	1683-1691	findings	abstract[83]	giv[83]	_	_
13-3	1692-1700	indicate	_	_	_	_
13-4	1701-1705	that	_	_	_	_
13-5	1706-1711	there	_	_	_	_
13-6	1712-1714	is	_	_	_	_
13-7	1715-1716	a	abstract[84]	new[84]	_	_
13-8	1717-1725	baseline	abstract[84]	new[84]	_	_
13-9	1726-1731	state	abstract[84]	new[84]	_	_
13-10	1732-1734	of	abstract[84]	new[84]	_	_
13-11	1735-1745	trigeminal	abstract[84]|abstract[85]	new[84]|giv[85]	coref	16-9[104_85]
13-12	1746-1759	sensitization	abstract[84]|abstract[85]	new[84]|giv[85]	_	_
13-13	1760-1762	in	abstract[84]|abstract[85]	new[84]|giv[85]	_	_
13-14	1763-1765	CH	abstract[84]|abstract[85]|abstract	new[84]|giv[85]|giv	coref	16-12
13-15	1766-1778	predisposing	abstract[84]|abstract[85]	new[84]|giv[85]	_	_
13-16	1779-1781	to	abstract[84]|abstract[85]	new[84]|giv[85]	_	_
13-17	1782-1789	periods	abstract[84]|abstract[85]|time[87]	new[84]|giv[85]|giv[87]	_	_
13-18	1790-1792	of	abstract[84]|abstract[85]|time[87]	new[84]|giv[85]|giv[87]	_	_
13-19	1793-1797	pain	abstract[84]|abstract[85]|time[87]|abstract	new[84]|giv[85]|giv[87]|giv	ana	14-3
13-20	1798-1799	.	_	_	_	_

#Text=Alternatively , it is also possible that the altered nociceptive processing could be induced by repetitive headache attacks of high intensity and then maintained without the presence of any nociceptive stimuli during the remission phase .
14-1	1800-1813	Alternatively	_	_	_	_
14-2	1814-1815	,	_	_	_	_
14-3	1816-1818	it	abstract	giv	coref	17-2
14-4	1819-1821	is	_	_	_	_
14-5	1822-1826	also	_	_	_	_
14-6	1827-1835	possible	_	_	_	_
14-7	1836-1840	that	_	_	_	_
14-8	1841-1844	the	abstract[90]	new[90]	_	_
14-9	1845-1852	altered	abstract[90]	new[90]	_	_
14-10	1853-1864	nociceptive	abstract[90]	new[90]	_	_
14-11	1865-1875	processing	abstract[90]	new[90]	_	_
14-12	1876-1881	could	_	_	_	_
14-13	1882-1884	be	_	_	_	_
14-14	1885-1892	induced	_	_	_	_
14-15	1893-1895	by	_	_	_	_
14-16	1896-1906	repetitive	event[92]	new[92]	_	_
14-17	1907-1915	headache	abstract|event[92]	new|new[92]	coref	21-19[147_0]
14-18	1916-1923	attacks	event[92]	new[92]	_	_
14-19	1924-1926	of	event[92]	new[92]	_	_
14-20	1927-1931	high	event[92]|abstract[93]	new[92]|new[93]	_	_
14-21	1932-1941	intensity	event[92]|abstract[93]	new[92]|new[93]	_	_
14-22	1942-1945	and	_	_	_	_
14-23	1946-1950	then	_	_	_	_
14-24	1951-1961	maintained	_	_	_	_
14-25	1962-1969	without	_	_	_	_
14-26	1970-1973	the	abstract[94]	new[94]	_	_
14-27	1974-1982	presence	abstract[94]	new[94]	_	_
14-28	1983-1985	of	abstract[94]	new[94]	_	_
14-29	1986-1989	any	abstract[94]|abstract[95]	new[94]|new[95]	coref	15-10[100_95]
14-30	1990-2001	nociceptive	abstract[94]|abstract[95]	new[94]|new[95]	_	_
14-31	2002-2009	stimuli	abstract[94]|abstract[95]	new[94]|new[95]	_	_
14-32	2010-2016	during	abstract[94]|abstract[95]	new[94]|new[95]	_	_
14-33	2017-2020	the	abstract[94]|abstract[95]|abstract[97]	new[94]|new[95]|giv[97]	coref	31-14[222_97]
14-34	2021-2030	remission	abstract[94]|abstract[95]|event|abstract[97]	new[94]|new[95]|giv|giv[97]	coref	31-15
14-35	2031-2036	phase	abstract[94]|abstract[95]|abstract[97]	new[94]|new[95]|giv[97]	_	_
14-36	2037-2038	.	_	_	_	_

#Text=Indeed , the occurrence of long-term potentiation induced by nociceptive stimuli has been suggested in other primary headaches .
15-1	2039-2045	Indeed	_	_	_	_
15-2	2046-2047	,	_	_	_	_
15-3	2048-2051	the	event[98]	new[98]	_	_
15-4	2052-2062	occurrence	event[98]	new[98]	_	_
15-5	2063-2065	of	event[98]	new[98]	_	_
15-6	2066-2075	long-term	event[98]|abstract[99]	new[98]|new[99]	_	_
15-7	2076-2088	potentiation	event[98]|abstract[99]	new[98]|new[99]	_	_
15-8	2089-2096	induced	event[98]|abstract[99]	new[98]|new[99]	_	_
15-9	2097-2099	by	event[98]|abstract[99]	new[98]|new[99]	_	_
15-10	2100-2111	nociceptive	event[98]|abstract[99]|abstract[100]	new[98]|new[99]|giv[100]	_	_
15-11	2112-2119	stimuli	event[98]|abstract[99]|abstract[100]	new[98]|new[99]|giv[100]	_	_
15-12	2120-2123	has	_	_	_	_
15-13	2124-2128	been	_	_	_	_
15-14	2129-2138	suggested	_	_	_	_
15-15	2139-2141	in	_	_	_	_
15-16	2142-2147	other	abstract[101]	giv[101]	coref	21-13[145_101]
15-17	2148-2155	primary	abstract[101]	giv[101]	_	_
15-18	2156-2165	headaches	abstract[101]	giv[101]	_	_
15-19	2166-2167	.	_	_	_	_

#Text=However , we cannot confirm the presence of central sensitization in CH , since PPTs represent a static outcome and dynamic measures of nociception would be needed .
16-1	2168-2175	However	_	_	_	_
16-2	2176-2177	,	_	_	_	_
16-3	2178-2180	we	person	giv	ana	19-3
16-4	2181-2187	cannot	_	_	_	_
16-5	2188-2195	confirm	_	_	_	_
16-6	2196-2199	the	abstract[103]	new[103]	_	_
16-7	2200-2208	presence	abstract[103]	new[103]	_	_
16-8	2209-2211	of	abstract[103]	new[103]	_	_
16-9	2212-2219	central	abstract[103]|abstract[104]	new[103]|giv[104]	_	_
16-10	2220-2233	sensitization	abstract[103]|abstract[104]	new[103]|giv[104]	_	_
16-11	2234-2236	in	_	_	_	_
16-12	2237-2239	CH	abstract	giv	coref	18-17[126_0]
16-13	2240-2241	,	_	_	_	_
16-14	2242-2247	since	_	_	_	_
16-15	2248-2252	PPTs	abstract	giv	_	_
16-16	2253-2262	represent	_	_	_	_
16-17	2263-2264	a	abstract[107]	new[107]	_	_
16-18	2265-2271	static	abstract[107]	new[107]	_	_
16-19	2272-2279	outcome	abstract[107]	new[107]	_	_
16-20	2280-2283	and	_	_	_	_
16-21	2284-2291	dynamic	abstract[108]	new[108]	_	_
16-22	2292-2300	measures	abstract[108]	new[108]	_	_
16-23	2301-2303	of	abstract[108]	new[108]	_	_
16-24	2304-2315	nociception	abstract[108]|abstract	new[108]|new	_	_
16-25	2316-2321	would	_	_	_	_
16-26	2322-2324	be	_	_	_	_
16-27	2325-2331	needed	_	_	_	_
16-28	2332-2333	.	_	_	_	_

#Text=Pressure pain sensitivity mapping based on multi-site recordings has previously been documented as a useful technique for visualizing the spatial topographic distribution of pain sensitivity .
17-1	2334-2342	Pressure	person|abstract[112]|abstract[113]	new|giv[112]|giv[113]	coref	17-24[118_112]
17-2	2343-2347	pain	abstract|abstract[112]|abstract[113]	giv|giv[112]|giv[113]	coref	17-24
17-3	2348-2359	sensitivity	abstract[112]|abstract[113]	giv[112]|giv[113]	_	_
17-4	2360-2367	mapping	abstract[113]	giv[113]	_	_
17-5	2368-2373	based	abstract[113]	giv[113]	_	_
17-6	2374-2376	on	abstract[113]	giv[113]	_	_
17-7	2377-2387	multi-site	abstract[113]|abstract[114]	giv[113]|new[114]	_	_
17-8	2388-2398	recordings	abstract[113]|abstract[114]	giv[113]|new[114]	_	_
17-9	2399-2402	has	_	_	_	_
17-10	2403-2413	previously	_	_	_	_
17-11	2414-2418	been	_	_	_	_
17-12	2419-2429	documented	_	_	_	_
17-13	2430-2432	as	_	_	_	_
17-14	2433-2434	a	abstract[115]	new[115]	_	_
17-15	2435-2441	useful	abstract[115]	new[115]	_	_
17-16	2442-2451	technique	abstract[115]	new[115]	_	_
17-17	2452-2455	for	abstract[115]	new[115]	_	_
17-18	2456-2467	visualizing	abstract[115]	new[115]	_	_
17-19	2468-2471	the	abstract[115]|abstract[116]	new[115]|new[116]	coref	24-15[159_116]
17-20	2472-2479	spatial	abstract[115]|abstract[116]	new[115]|new[116]	_	_
17-21	2480-2491	topographic	abstract[115]|abstract[116]	new[115]|new[116]	_	_
17-22	2492-2504	distribution	abstract[115]|abstract[116]	new[115]|new[116]	_	_
17-23	2505-2507	of	abstract[115]|abstract[116]	new[115]|new[116]	_	_
17-24	2508-2512	pain	abstract[115]|abstract[116]|abstract|abstract[118]	new[115]|new[116]|giv|giv[118]	coref|coref	18-11|18-11[123_118]
17-25	2513-2524	sensitivity	abstract[115]|abstract[116]|abstract[118]	new[115]|new[116]|giv[118]	_	_
17-26	2525-2526	.	_	_	_	_

#Text=This study is the first attempt at assessing topographical pressure pain sensitivity maps in patients with episodic CH .
18-1	2527-2531	This	event[119]	new[119]	coref	18-4[120_119]
18-2	2532-2537	study	event[119]	new[119]	_	_
18-3	2538-2540	is	_	_	_	_
18-4	2541-2544	the	event[120]	giv[120]	coref	21-4[143_120]
18-5	2545-2550	first	event[120]	giv[120]	_	_
18-6	2551-2558	attempt	event[120]	giv[120]	_	_
18-7	2559-2561	at	event[120]	giv[120]	_	_
18-8	2562-2571	assessing	event[120]	giv[120]	_	_
18-9	2572-2585	topographical	event[120]|abstract[124]	giv[120]|new[124]	coref	35-10[258_124]
18-10	2586-2594	pressure	event[120]|abstract|abstract[124]	giv[120]|giv|new[124]	coref	24-10
18-11	2595-2599	pain	event[120]|abstract|abstract[123]|abstract[124]	giv[120]|giv|giv[123]|new[124]	coref|coref	19-16[132_123]|19-25
18-12	2600-2611	sensitivity	event[120]|abstract[123]|abstract[124]	giv[120]|giv[123]|new[124]	_	_
18-13	2612-2616	maps	event[120]|abstract[124]	giv[120]|new[124]	_	_
18-14	2617-2619	in	event[120]	giv[120]	_	_
18-15	2620-2628	patients	event[120]|person[125]	giv[120]|giv[125]	coref	19-7[130_125]
18-16	2629-2633	with	event[120]|person[125]	giv[120]|giv[125]	_	_
18-17	2634-2642	episodic	event[120]|person[125]|abstract[126]	giv[120]|giv[125]|giv[126]	coref	19-7[0_126]
18-18	2643-2645	CH	event[120]|person[125]|abstract[126]	giv[120]|giv[125]|giv[126]	_	_
18-19	2646-2647	.	_	_	_	_

#Text=According to our findings , in CH patients , there is an anterior-to-posterior gradient of sensitivity within the temporalis muscle so that the lowest pain thresholds are located in the anterior region of the muscle .
19-1	2648-2657	According	_	_	_	_
19-2	2658-2660	to	_	_	_	_
19-3	2661-2664	our	person|abstract[128]	giv|giv[128]	ana	26-3
19-4	2665-2673	findings	abstract[128]	giv[128]	_	_
19-5	2674-2675	,	_	_	_	_
19-6	2676-2678	in	_	_	_	_
19-7	2679-2681	CH	abstract|person[130]	giv|giv[130]	coref	26-32[185_0]
19-8	2682-2690	patients	person[130]	giv[130]	_	_
19-9	2691-2692	,	_	_	_	_
19-10	2693-2698	there	_	_	_	_
19-11	2699-2701	is	_	_	_	_
19-12	2702-2704	an	abstract[131]	new[131]	coref	20-1[138_131]
19-13	2705-2726	anterior-to-posterior	abstract[131]	new[131]	_	_
19-14	2727-2735	gradient	abstract[131]	new[131]	_	_
19-15	2736-2738	of	abstract[131]	new[131]	_	_
19-16	2739-2750	sensitivity	abstract[131]|abstract[132]	new[131]|giv[132]	coref	27-18[189_132]
19-17	2751-2757	within	abstract[131]|abstract[132]	new[131]|giv[132]	_	_
19-18	2758-2761	the	abstract[131]|abstract[132]|object[133]	new[131]|giv[132]|giv[133]	coref	19-34[137_133]
19-19	2762-2772	temporalis	abstract[131]|abstract[132]|object[133]	new[131]|giv[132]|giv[133]	_	_
19-20	2773-2779	muscle	abstract[131]|abstract[132]|object[133]	new[131]|giv[132]|giv[133]	_	_
19-21	2780-2782	so	_	_	_	_
19-22	2783-2787	that	_	_	_	_
19-23	2788-2791	the	abstract[135]	new[135]	_	_
19-24	2792-2798	lowest	abstract[135]	new[135]	_	_
19-25	2799-2803	pain	abstract|abstract[135]	giv|new[135]	coref	24-10[157_0]
19-26	2804-2814	thresholds	abstract[135]	new[135]	_	_
19-27	2815-2818	are	_	_	_	_
19-28	2819-2826	located	_	_	_	_
19-29	2827-2829	in	_	_	_	_
19-30	2830-2833	the	place[136]	giv[136]	coref	20-11[140_136]
19-31	2834-2842	anterior	place[136]	giv[136]	_	_
19-32	2843-2849	region	place[136]	giv[136]	_	_
19-33	2850-2852	of	place[136]	giv[136]	_	_
19-34	2853-2856	the	place[136]|object[137]	giv[136]|giv[137]	coref	25-14[0_137]
19-35	2857-2863	muscle	place[136]|object[137]	giv[136]|giv[137]	_	_
19-36	2864-2865	.	_	_	_	_

#Text=This gradient is not present in headache-free controls , where the most sensitive area was located in the mid-muscle belly .
20-1	2866-2870	This	abstract[138]	giv[138]	coref	22-6[150_138]
20-2	2871-2879	gradient	abstract[138]	giv[138]	_	_
20-3	2880-2882	is	_	_	_	_
20-4	2883-2886	not	_	_	_	_
20-5	2887-2894	present	_	_	_	_
20-6	2895-2897	in	_	_	_	_
20-7	2898-2911	headache-free	abstract[139]	giv[139]	coref	28-24[201_139]
20-8	2912-2920	controls	abstract[139]	giv[139]	_	_
20-9	2921-2922	,	abstract[139]	giv[139]	_	_
20-10	2923-2928	where	abstract[139]	giv[139]	_	_
20-11	2929-2932	the	abstract[139]|place[140]	giv[139]|giv[140]	coref	26-26[183_140]
20-12	2933-2937	most	abstract[139]|place[140]	giv[139]|giv[140]	_	_
20-13	2938-2947	sensitive	abstract[139]|place[140]	giv[139]|giv[140]	_	_
20-14	2948-2952	area	abstract[139]|place[140]	giv[139]|giv[140]	_	_
20-15	2953-2956	was	abstract[139]	giv[139]	_	_
20-16	2957-2964	located	abstract[139]	giv[139]	_	_
20-17	2965-2967	in	abstract[139]	giv[139]	_	_
20-18	2968-2971	the	abstract[139]|object[141]	giv[139]|new[141]	_	_
20-19	2972-2982	mid-muscle	abstract[139]|object[141]	giv[139]|new[141]	_	_
20-20	2983-2988	belly	abstract[139]|object[141]	giv[139]|new[141]	_	_
20-21	2989-2990	.	_	_	_	_

#Text=The results of this study are similar to those previously described in other primary headaches , such as tension-type headache and unilateral migraine .
21-1	2991-2994	The	abstract[142]	giv[142]	_	_
21-2	2995-3002	results	abstract[142]	giv[142]	_	_
21-3	3003-3005	of	abstract[142]	giv[142]	_	_
21-4	3006-3010	this	abstract[142]|event[143]	giv[142]|giv[143]	ana	21-9[144_143]
21-5	3011-3016	study	abstract[142]|event[143]	giv[142]|giv[143]	_	_
21-6	3017-3020	are	_	_	_	_
21-7	3021-3028	similar	_	_	_	_
21-8	3029-3031	to	_	_	_	_
21-9	3032-3037	those	event[144]	giv[144]	coref	30-7[216_144]
21-10	3038-3048	previously	event[144]	giv[144]	_	_
21-11	3049-3058	described	event[144]	giv[144]	_	_
21-12	3059-3061	in	event[144]	giv[144]	_	_
21-13	3062-3067	other	event[144]|abstract[145]	giv[144]|giv[145]	coref	24-19[160_145]
21-14	3068-3075	primary	event[144]|abstract[145]	giv[144]|giv[145]	_	_
21-15	3076-3085	headaches	event[144]|abstract[145]	giv[144]|giv[145]	_	_
21-16	3086-3087	,	event[144]|abstract[145]	giv[144]|giv[145]	_	_
21-17	3088-3092	such	event[144]|abstract[145]	giv[144]|giv[145]	_	_
21-18	3093-3095	as	event[144]|abstract[145]	giv[144]|giv[145]	_	_
21-19	3096-3108	tension-type	event[144]|abstract[145]|abstract|abstract[147]	giv[144]|giv[145]|new|giv[147]	coref	24-36[0_147]
21-20	3109-3117	headache	event[144]|abstract[145]|abstract[147]	giv[144]|giv[145]|giv[147]	_	_
21-21	3118-3121	and	event[144]|abstract[145]	giv[144]|giv[145]	_	_
21-22	3122-3132	unilateral	event[144]|abstract[145]|event[148]	giv[144]|giv[145]|giv[148]	_	_
21-23	3133-3141	migraine	event[144]|abstract[145]|event[148]	giv[144]|giv[145]|giv[148]	_	_
21-24	3142-3143	.	_	_	_	_

#Text=To determine the mechanisms underlying the anterior-to-posterior gradient is beyond the scope of the current paper .
22-1	3144-3146	To	_	_	_	_
22-2	3147-3156	determine	_	_	_	_
22-3	3157-3160	the	abstract[149]	new[149]	_	_
22-4	3161-3171	mechanisms	abstract[149]	new[149]	_	_
22-5	3172-3182	underlying	abstract[149]	new[149]	_	_
22-6	3183-3186	the	abstract[149]|abstract[150]	new[149]|giv[150]	coref	25-3[166_150]
22-7	3187-3208	anterior-to-posterior	abstract[149]|abstract[150]	new[149]|giv[150]	_	_
22-8	3209-3217	gradient	abstract[149]|abstract[150]	new[149]|giv[150]	_	_
22-9	3218-3220	is	_	_	_	_
22-10	3221-3227	beyond	_	_	_	_
22-11	3228-3231	the	abstract[151]	new[151]	_	_
22-12	3232-3237	scope	abstract[151]	new[151]	_	_
22-13	3238-3240	of	abstract[151]	new[151]	_	_
22-14	3241-3244	the	abstract[151]|abstract[152]	new[151]|new[152]	_	_
22-15	3245-3252	current	abstract[151]|abstract[152]	new[151]|new[152]	_	_
22-16	3253-3258	paper	abstract[151]|abstract[152]	new[151]|new[152]	_	_
22-17	3259-3260	.	_	_	_	_

#Text=However , two hypotheses can be stated .
23-1	3261-3268	However	_	_	_	_
23-2	3269-3270	,	_	_	_	_
23-3	3271-3274	two	abstract[153]	new[153]	_	_
23-4	3275-3285	hypotheses	abstract[153]	new[153]	_	_
23-5	3286-3289	can	_	_	_	_
23-6	3290-3292	be	_	_	_	_
23-7	3293-3299	stated	_	_	_	_
23-8	3300-3301	.	_	_	_	_

#Text=First , sensitization of trigeminal pathways could generate a pressure pain hyperalgesic pattern with an anterior-to-posterior distribution in primary headaches , regardless of unilateral or bilateral location of the symptoms or the specific type of headache .
24-1	3302-3307	First	_	_	_	_
24-2	3308-3309	,	_	_	_	_
24-3	3310-3323	sensitization	abstract[154]	new[154]	coref	38-28[277_154]
24-4	3324-3326	of	abstract[154]	new[154]	_	_
24-5	3327-3337	trigeminal	abstract[154]|abstract[155]	new[154]|giv[155]	_	_
24-6	3338-3346	pathways	abstract[154]|abstract[155]	new[154]|giv[155]	_	_
24-7	3347-3352	could	_	_	_	_
24-8	3353-3361	generate	_	_	_	_
24-9	3362-3363	a	abstract[158]	new[158]	_	_
24-10	3364-3372	pressure	abstract|abstract[157]|abstract[158]	giv|giv[157]|new[158]	coref|coref	26-22|26-23[0_157]
24-11	3373-3377	pain	abstract[157]|abstract[158]	giv[157]|new[158]	_	_
24-12	3378-3390	hyperalgesic	abstract[158]	new[158]	_	_
24-13	3391-3398	pattern	abstract[158]	new[158]	_	_
24-14	3399-3403	with	abstract[158]	new[158]	_	_
24-15	3404-3406	an	abstract[158]|abstract[159]	new[158]|giv[159]	_	_
24-16	3407-3428	anterior-to-posterior	abstract[158]|abstract[159]	new[158]|giv[159]	_	_
24-17	3429-3441	distribution	abstract[158]|abstract[159]	new[158]|giv[159]	_	_
24-18	3442-3444	in	_	_	_	_
24-19	3445-3452	primary	abstract[160]	giv[160]	coref	25-28[0_160]
24-20	3453-3462	headaches	abstract[160]	giv[160]	_	_
24-21	3463-3464	,	_	_	_	_
24-22	3465-3475	regardless	_	_	_	_
24-23	3476-3478	of	_	_	_	_
24-24	3479-3489	unilateral	place[161]	new[161]	_	_
24-25	3490-3492	or	place[161]	new[161]	_	_
24-26	3493-3502	bilateral	place[161]	new[161]	_	_
24-27	3503-3511	location	place[161]	new[161]	_	_
24-28	3512-3514	of	place[161]	new[161]	_	_
24-29	3515-3518	the	place[161]|abstract[162]|abstract[163]	new[161]|giv[162]|giv[163]	coref	24-29[163_162]
24-30	3519-3527	symptoms	place[161]|abstract[162]|abstract[163]	new[161]|giv[162]|giv[163]	_	_
24-31	3528-3530	or	place[161]|abstract[163]	new[161]|giv[163]	_	_
24-32	3531-3534	the	place[161]|abstract[163]|abstract[164]	new[161]|giv[163]|new[164]	_	_
24-33	3535-3543	specific	place[161]|abstract[163]|abstract[164]	new[161]|giv[163]|new[164]	_	_
24-34	3544-3548	type	place[161]|abstract[163]|abstract[164]	new[161]|giv[163]|new[164]	_	_
24-35	3549-3551	of	place[161]|abstract[163]|abstract[164]	new[161]|giv[163]|new[164]	_	_
24-36	3552-3560	headache	place[161]|abstract[163]|abstract[164]|abstract	new[161]|giv[163]|new[164]|giv	coref	28-21
24-37	3561-3562	.	_	_	_	_

#Text=Secondly , an anterior-to-posterior gradient could be also related to different distribution of muscle nociceptors between the different areas of the temporalis muscle that could predispose to headaches , but this cannot be confirmed until histological studies are conducted .
25-1	3563-3571	Secondly	_	_	_	_
25-2	3572-3573	,	_	_	_	_
25-3	3574-3576	an	abstract[166]	giv[166]	coref	35-15[259_166]
25-4	3577-3598	anterior-to-posterior	abstract[166]	giv[166]	_	_
25-5	3599-3607	gradient	abstract[166]	giv[166]	_	_
25-6	3608-3613	could	_	_	_	_
25-7	3614-3616	be	_	_	_	_
25-8	3617-3621	also	_	_	_	_
25-9	3622-3629	related	_	_	_	_
25-10	3630-3632	to	_	_	_	_
25-11	3633-3642	different	abstract[167]	new[167]	ana	25-31[0_167]
25-12	3643-3655	distribution	abstract[167]	new[167]	_	_
25-13	3656-3658	of	abstract[167]	new[167]	_	_
25-14	3659-3665	muscle	abstract[167]|object|abstract[169]	new[167]|giv|new[169]	coref	25-21[171_0]
25-15	3666-3677	nociceptors	abstract[167]|abstract[169]	new[167]|new[169]	_	_
25-16	3678-3685	between	abstract[167]|abstract[169]	new[167]|new[169]	_	_
25-17	3686-3689	the	abstract[167]|abstract[169]|place[170]	new[167]|new[169]|new[170]	_	_
25-18	3690-3699	different	abstract[167]|abstract[169]|place[170]	new[167]|new[169]|new[170]	_	_
25-19	3700-3705	areas	abstract[167]|abstract[169]|place[170]	new[167]|new[169]|new[170]	_	_
25-20	3706-3708	of	abstract[167]|abstract[169]|place[170]	new[167]|new[169]|new[170]	_	_
25-21	3709-3712	the	abstract[167]|abstract[169]|place[170]|object[171]	new[167]|new[169]|new[170]|giv[171]	_	_
25-22	3713-3723	temporalis	abstract[167]|abstract[169]|place[170]|object[171]	new[167]|new[169]|new[170]|giv[171]	_	_
25-23	3724-3730	muscle	abstract[167]|abstract[169]|place[170]|object[171]	new[167]|new[169]|new[170]|giv[171]	_	_
25-24	3731-3735	that	abstract[167]|abstract[169]|place[170]|object[171]	new[167]|new[169]|new[170]|giv[171]	_	_
25-25	3736-3741	could	abstract[167]|abstract[169]|place[170]|object[171]	new[167]|new[169]|new[170]|giv[171]	_	_
25-26	3742-3752	predispose	abstract[167]|abstract[169]|place[170]|object[171]	new[167]|new[169]|new[170]|giv[171]	_	_
25-27	3753-3755	to	abstract[167]|abstract[169]|place[170]|object[171]	new[167]|new[169]|new[170]|giv[171]	_	_
25-28	3756-3765	headaches	abstract[167]|abstract[169]|place[170]|object[171]|abstract	new[167]|new[169]|new[170]|giv[171]|giv	coref	27-23[192_0]
25-29	3766-3767	,	_	_	_	_
25-30	3768-3771	but	_	_	_	_
25-31	3772-3776	this	abstract	giv	_	_
25-32	3777-3783	cannot	_	_	_	_
25-33	3784-3786	be	_	_	_	_
25-34	3787-3796	confirmed	_	_	_	_
25-35	3797-3802	until	_	_	_	_
25-36	3803-3815	histological	abstract[174]	giv[174]	coref	28-18[198_174]
25-37	3816-3823	studies	abstract[174]	giv[174]	_	_
25-38	3824-3827	are	_	_	_	_
25-39	3828-3837	conducted	_	_	_	_
25-40	3838-3839	.	_	_	_	_

#Text=Additionally , we also found that the levels of anxiety and depression do not seem to have a significant influence on pressure pain hyperalgesia within the trigeminal area in men with episodic CH .
26-1	3840-3852	Additionally	_	_	_	_
26-2	3853-3854	,	_	_	_	_
26-3	3855-3857	we	person	giv	ana	30-1
26-4	3858-3862	also	_	_	_	_
26-5	3863-3868	found	_	_	_	_
26-6	3869-3873	that	_	_	_	_
26-7	3874-3877	the	abstract[176]	new[176]	_	_
26-8	3878-3884	levels	abstract[176]	new[176]	_	_
26-9	3885-3887	of	abstract[176]	new[176]	_	_
26-10	3888-3895	anxiety	abstract[176]|abstract	new[176]|new	_	_
26-11	3896-3899	and	abstract[176]	new[176]	_	_
26-12	3900-3910	depression	abstract[176]|abstract	new[176]|new	_	_
26-13	3911-3913	do	_	_	_	_
26-14	3914-3917	not	_	_	_	_
26-15	3918-3922	seem	_	_	_	_
26-16	3923-3925	to	_	_	_	_
26-17	3926-3930	have	_	_	_	_
26-18	3931-3932	a	abstract[179]	new[179]	_	_
26-19	3933-3944	significant	abstract[179]	new[179]	_	_
26-20	3945-3954	influence	abstract[179]	new[179]	_	_
26-21	3955-3957	on	abstract[179]	new[179]	_	_
26-22	3958-3966	pressure	abstract[179]|abstract|abstract[182]	new[179]|giv|giv[182]	coref	27-20
26-23	3967-3971	pain	abstract[179]|abstract|abstract[182]	new[179]|giv|giv[182]	coref	27-20[191_0]
26-24	3972-3984	hyperalgesia	abstract[179]|abstract[182]	new[179]|giv[182]	_	_
26-25	3985-3991	within	abstract[179]|abstract[182]	new[179]|giv[182]	_	_
26-26	3992-3995	the	abstract[179]|abstract[182]|place[183]	new[179]|giv[182]|giv[183]	coref	29-13[208_183]
26-27	3996-4006	trigeminal	abstract[179]|abstract[182]|place[183]	new[179]|giv[182]|giv[183]	_	_
26-28	4007-4011	area	abstract[179]|abstract[182]|place[183]	new[179]|giv[182]|giv[183]	_	_
26-29	4012-4014	in	_	_	_	_
26-30	4015-4018	men	person[184]	new[184]	coref	31-9[219_184]
26-31	4019-4023	with	person[184]	new[184]	_	_
26-32	4024-4032	episodic	person[184]|abstract[185]	new[184]|giv[185]	ana	27-1[0_185]
26-33	4033-4035	CH	person[184]|abstract[185]	new[184]|giv[185]	_	_
26-34	4036-4037	.	_	_	_	_

#Text=It would be interesting to investigate other potential psychological factors related to the observed anterior-to-posterior distribution of sensitivity to pressure pain in primary headaches .
27-1	4038-4040	It	abstract	giv	coref	29-28
27-2	4041-4046	would	_	_	_	_
27-3	4047-4049	be	_	_	_	_
27-4	4050-4061	interesting	_	_	_	_
27-5	4062-4064	to	_	_	_	_
27-6	4065-4076	investigate	_	_	_	_
27-7	4077-4082	other	abstract[187]	new[187]	_	_
27-8	4083-4092	potential	abstract[187]	new[187]	_	_
27-9	4093-4106	psychological	abstract[187]	new[187]	_	_
27-10	4107-4114	factors	abstract[187]	new[187]	_	_
27-11	4115-4122	related	abstract[187]	new[187]	_	_
27-12	4123-4125	to	abstract[187]	new[187]	_	_
27-13	4126-4129	the	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-14	4130-4138	observed	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-15	4139-4160	anterior-to-posterior	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-16	4161-4173	distribution	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-17	4174-4176	of	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-18	4177-4188	sensitivity	abstract[187]|abstract[188]|abstract[189]	new[187]|new[188]|giv[189]	coref	28-10[195_189]
27-19	4189-4191	to	abstract[187]|abstract[188]|abstract[189]	new[187]|new[188]|giv[189]	_	_
27-20	4192-4200	pressure	abstract[187]|abstract[188]|abstract[189]|abstract|abstract[191]	new[187]|new[188]|giv[189]|giv|giv[191]	coref|coref	28-12|28-12[197_191]
27-21	4201-4205	pain	abstract[187]|abstract[188]|abstract[189]|abstract[191]	new[187]|new[188]|giv[189]|giv[191]	_	_
27-22	4206-4208	in	abstract[187]|abstract[188]|abstract[189]	new[187]|new[188]|giv[189]	_	_
27-23	4209-4216	primary	abstract[187]|abstract[188]|abstract[189]|abstract[192]	new[187]|new[188]|giv[189]|giv[192]	_	_
27-24	4217-4226	headaches	abstract[187]|abstract[188]|abstract[189]|abstract[192]	new[187]|new[188]|giv[189]|giv[192]	_	_
27-25	4227-4228	.	_	_	_	_

#Text=In fact , differences in the spatial distribution of sensitivity to pressure pain should be considered in future studies comparing headache populations and headache-free controls , since taking the same point as a reference could be biased .
28-1	4229-4231	In	_	_	_	_
28-2	4232-4236	fact	_	_	_	_
28-3	4237-4238	,	_	_	_	_
28-4	4239-4250	differences	abstract[193]	new[193]	_	_
28-5	4251-4253	in	abstract[193]	new[193]	_	_
28-6	4254-4257	the	abstract[193]|abstract[194]	new[193]|new[194]	_	_
28-7	4258-4265	spatial	abstract[193]|abstract[194]	new[193]|new[194]	_	_
28-8	4266-4278	distribution	abstract[193]|abstract[194]	new[193]|new[194]	_	_
28-9	4279-4281	of	abstract[193]|abstract[194]	new[193]|new[194]	_	_
28-10	4282-4293	sensitivity	abstract[193]|abstract[194]|abstract[195]	new[193]|new[194]|giv[195]	coref	33-23[240_195]
28-11	4294-4296	to	abstract[193]|abstract[194]|abstract[195]	new[193]|new[194]|giv[195]	_	_
28-12	4297-4305	pressure	abstract[193]|abstract[194]|abstract[195]|abstract|abstract[197]	new[193]|new[194]|giv[195]|giv|giv[197]	coref|coref	29-10|29-10[207_197]
28-13	4306-4310	pain	abstract[193]|abstract[194]|abstract[195]|abstract[197]	new[193]|new[194]|giv[195]|giv[197]	_	_
28-14	4311-4317	should	_	_	_	_
28-15	4318-4320	be	_	_	_	_
28-16	4321-4331	considered	_	_	_	_
28-17	4332-4334	in	_	_	_	_
28-18	4335-4341	future	abstract[198]	giv[198]	coref	36-1[264_198]
28-19	4342-4349	studies	abstract[198]	giv[198]	_	_
28-20	4350-4359	comparing	abstract[198]	giv[198]	_	_
28-21	4360-4368	headache	abstract[198]|abstract|abstract[200]	giv[198]|giv|new[200]	_	_
28-22	4369-4380	populations	abstract[198]|abstract[200]	giv[198]|new[200]	_	_
28-23	4381-4384	and	abstract[198]	giv[198]	_	_
28-24	4385-4398	headache-free	abstract[198]|abstract[201]	giv[198]|giv[201]	_	_
28-25	4399-4407	controls	abstract[198]|abstract[201]	giv[198]|giv[201]	_	_
28-26	4408-4409	,	_	_	_	_
28-27	4410-4415	since	_	_	_	_
28-28	4416-4422	taking	_	_	_	_
28-29	4423-4426	the	abstract[202]	new[202]	_	_
28-30	4427-4431	same	abstract[202]	new[202]	_	_
28-31	4432-4437	point	abstract[202]	new[202]	_	_
28-32	4438-4440	as	_	_	_	_
28-33	4441-4442	a	abstract[203]	new[203]	_	_
28-34	4443-4452	reference	abstract[203]	new[203]	_	_
28-35	4453-4458	could	_	_	_	_
28-36	4459-4461	be	_	_	_	_
28-37	4462-4468	biased	_	_	_	_
28-38	4469-4470	.	_	_	_	_

#Text=In addition , changes in the spatial distribution of pressure pain within the trigeminal area could be used to monitor the effects of treatment in individuals with CH .
29-1	4471-4473	In	_	_	_	_
29-2	4474-4482	addition	_	_	_	_
29-3	4483-4484	,	_	_	_	_
29-4	4485-4492	changes	abstract[204]	new[204]	_	_
29-5	4493-4495	in	abstract[204]	new[204]	_	_
29-6	4496-4499	the	abstract[204]|abstract[205]	new[204]|new[205]	_	_
29-7	4500-4507	spatial	abstract[204]|abstract[205]	new[204]|new[205]	_	_
29-8	4508-4520	distribution	abstract[204]|abstract[205]	new[204]|new[205]	_	_
29-9	4521-4523	of	abstract[204]|abstract[205]	new[204]|new[205]	_	_
29-10	4524-4532	pressure	abstract[204]|abstract[205]|abstract|abstract[207]	new[204]|new[205]|giv|giv[207]	coref|coref	33-23|33-24[0_207]
29-11	4533-4537	pain	abstract[204]|abstract[205]|abstract[207]	new[204]|new[205]|giv[207]	_	_
29-12	4538-4544	within	abstract[204]|abstract[205]|abstract[207]	new[204]|new[205]|giv[207]	_	_
29-13	4545-4548	the	abstract[204]|abstract[205]|abstract[207]|place[208]	new[204]|new[205]|giv[207]|giv[208]	_	_
29-14	4549-4559	trigeminal	abstract[204]|abstract[205]|abstract[207]|place[208]	new[204]|new[205]|giv[207]|giv[208]	_	_
29-15	4560-4564	area	abstract[204]|abstract[205]|abstract[207]|place[208]	new[204]|new[205]|giv[207]|giv[208]	_	_
29-16	4565-4570	could	_	_	_	_
29-17	4571-4573	be	_	_	_	_
29-18	4574-4578	used	_	_	_	_
29-19	4579-4581	to	_	_	_	_
29-20	4582-4589	monitor	_	_	_	_
29-21	4590-4593	the	abstract[209]	new[209]	_	_
29-22	4594-4601	effects	abstract[209]	new[209]	_	_
29-23	4602-4604	of	abstract[209]	new[209]	_	_
29-24	4605-4614	treatment	abstract[209]|event	new[209]|new	_	_
29-25	4615-4617	in	abstract[209]	new[209]	_	_
29-26	4618-4629	individuals	abstract[209]|person[211]	new[209]|giv[211]	_	_
29-27	4630-4634	with	abstract[209]|person[211]	new[209]|giv[211]	_	_
29-28	4635-4637	CH	abstract[209]|person[211]|abstract	new[209]|giv[211]|giv	coref	31-11[220_0]
29-29	4638-4639	.	_	_	_	_

#Text=We must recognize some limitations of our study .
30-1	4640-4642	We	person	giv	ana	30-7
30-2	4643-4647	must	_	_	_	_
30-3	4648-4657	recognize	_	_	_	_
30-4	4658-4662	some	abstract[214]	new[214]	_	_
30-5	4663-4674	limitations	abstract[214]	new[214]	_	_
30-6	4675-4677	of	abstract[214]	new[214]	_	_
30-7	4678-4681	our	abstract[214]|person|event[216]	new[214]|giv|giv[216]	ana	31-3
30-8	4682-4687	study	abstract[214]|event[216]	new[214]|giv[216]	_	_
30-9	4688-4689	.	_	_	_	_

#Text=First , our sample was only comprised of men with episodic CH in a remission phase .
31-1	4690-4695	First	_	_	_	_
31-2	4696-4697	,	_	_	_	_
31-3	4698-4701	our	person|object[218]	giv|new[218]	ana|coref	32-3|33-8[234_218]
31-4	4702-4708	sample	object[218]	new[218]	_	_
31-5	4709-4712	was	_	_	_	_
31-6	4713-4717	only	_	_	_	_
31-7	4718-4727	comprised	_	_	_	_
31-8	4728-4730	of	_	_	_	_
31-9	4731-4734	men	person[219]	giv[219]	coref	32-13[228_219]
31-10	4735-4739	with	person[219]	giv[219]	_	_
31-11	4740-4748	episodic	person[219]|abstract[220]	giv[219]|giv[220]	coref	32-10[0_220]
31-12	4749-4751	CH	person[219]|abstract[220]	giv[219]|giv[220]	_	_
31-13	4752-4754	in	person[219]|abstract[220]	giv[219]|giv[220]	_	_
31-14	4755-4756	a	person[219]|abstract[220]|abstract[222]	giv[219]|giv[220]|giv[222]	coref	32-23[231_222]
31-15	4757-4766	remission	person[219]|abstract[220]|event|abstract[222]	giv[219]|giv[220]|giv|giv[222]	_	_
31-16	4767-4772	phase	person[219]|abstract[220]|abstract[222]	giv[219]|giv[220]|giv[222]	_	_
31-17	4773-4774	.	_	_	_	_

#Text=Therefore , we cannot draw conclusions concerning women with CH , or men with chronic CH , or with episodic CH in an active phase .
32-1	4775-4784	Therefore	_	_	_	_
32-2	4785-4786	,	_	_	_	_
32-3	4787-4789	we	person	giv	ana	33-8
32-4	4790-4796	cannot	_	_	_	_
32-5	4797-4801	draw	_	_	_	_
32-6	4802-4813	conclusions	abstract	new	_	_
32-7	4814-4824	concerning	_	_	_	_
32-8	4825-4830	women	person[225]|person[226]	new[225]|new[226]	ana	33-16[0_226]
32-9	4831-4835	with	person[225]|person[226]	new[225]|new[226]	_	_
32-10	4836-4838	CH	person[225]|person[226]|abstract	new[225]|new[226]|giv	coref	32-15[229_0]
32-11	4839-4840	,	person[226]	new[226]	_	_
32-12	4841-4843	or	person[226]	new[226]	_	_
32-13	4844-4847	men	person[226]|person[228]	new[226]|giv[228]	coref	35-20[260_228]
32-14	4848-4852	with	person[226]|person[228]	new[226]|giv[228]	_	_
32-15	4853-4860	chronic	person[226]|person[228]|abstract[229]	new[226]|giv[228]|giv[229]	coref	32-20[230_229]
32-16	4861-4863	CH	person[226]|person[228]|abstract[229]	new[226]|giv[228]|giv[229]	_	_
32-17	4864-4865	,	_	_	_	_
32-18	4866-4868	or	_	_	_	_
32-19	4869-4873	with	_	_	_	_
32-20	4874-4882	episodic	abstract[230]	giv[230]	coref	34-33[0_230]
32-21	4883-4885	CH	abstract[230]	giv[230]	_	_
32-22	4886-4888	in	abstract[230]	giv[230]	_	_
32-23	4889-4891	an	abstract[230]|abstract[231]	giv[230]|giv[231]	coref	33-32[242_231]
32-24	4892-4898	active	abstract[230]|abstract[231]	giv[230]|giv[231]	_	_
32-25	4899-4904	phase	abstract[230]|abstract[231]	giv[230]|giv[231]	_	_
32-26	4905-4906	.	_	_	_	_

#Text=Secondly , depressive and anxiety levels of our sample were relatively low , thus , their potential role in spatial distribution of pressure pain sensitivity should be considered with caution at this stage .
33-1	4907-4915	Secondly	_	_	_	_
33-2	4916-4917	,	_	_	_	_
33-3	4918-4928	depressive	abstract[232]	new[232]	_	_
33-4	4929-4932	and	abstract[232]	new[232]	_	_
33-5	4933-4940	anxiety	abstract[232]	new[232]	_	_
33-6	4941-4947	levels	abstract[232]	new[232]	_	_
33-7	4948-4950	of	abstract[232]	new[232]	_	_
33-8	4951-4954	our	abstract[232]|person|object[234]	new[232]|giv|giv[234]	ana	34-3
33-9	4955-4961	sample	abstract[232]|object[234]	new[232]|giv[234]	_	_
33-10	4962-4966	were	_	_	_	_
33-11	4967-4977	relatively	_	_	_	_
33-12	4978-4981	low	_	_	_	_
33-13	4982-4983	,	_	_	_	_
33-14	4984-4988	thus	_	_	_	_
33-15	4989-4990	,	_	_	_	_
33-16	4991-4996	their	person|abstract[236]	giv|new[236]	_	_
33-17	4997-5006	potential	abstract[236]	new[236]	_	_
33-18	5007-5011	role	abstract[236]	new[236]	_	_
33-19	5012-5014	in	abstract[236]	new[236]	_	_
33-20	5015-5022	spatial	abstract[236]|abstract[237]	new[236]|new[237]	coref	34-21[248_237]
33-21	5023-5035	distribution	abstract[236]|abstract[237]	new[236]|new[237]	_	_
33-22	5036-5038	of	abstract[236]|abstract[237]	new[236]|new[237]	_	_
33-23	5039-5047	pressure	abstract[236]|abstract[237]|abstract|abstract[240]	new[236]|new[237]|giv|giv[240]	coref|coref	34-24|34-24[251_240]
33-24	5048-5052	pain	abstract[236]|abstract[237]|abstract|abstract[240]	new[236]|new[237]|giv|giv[240]	coref	34-25
33-25	5053-5064	sensitivity	abstract[236]|abstract[237]|abstract[240]	new[236]|new[237]|giv[240]	_	_
33-26	5065-5071	should	_	_	_	_
33-27	5072-5074	be	_	_	_	_
33-28	5075-5085	considered	_	_	_	_
33-29	5086-5090	with	_	_	_	_
33-30	5091-5098	caution	abstract	new	_	_
33-31	5099-5101	at	_	_	_	_
33-32	5102-5106	this	abstract[242]	giv[242]	_	_
33-33	5107-5112	stage	abstract[242]	giv[242]	_	_
33-34	5113-5114	.	_	_	_	_

#Text=Thirdly , we used a cross-sectional design , which does not permit to determine a cause and effect relationship between spatial distribution of pressure pain sensitivity and the development or maintenance of CH .
34-1	5115-5122	Thirdly	_	_	_	_
34-2	5123-5124	,	_	_	_	_
34-3	5125-5127	we	person	giv	ana	37-3
34-4	5128-5132	used	_	_	_	_
34-5	5133-5134	a	abstract[244]	new[244]	_	_
34-6	5135-5150	cross-sectional	abstract[244]	new[244]	_	_
34-7	5151-5157	design	abstract[244]	new[244]	_	_
34-8	5158-5159	,	abstract[244]	new[244]	_	_
34-9	5160-5165	which	abstract[244]	new[244]	_	_
34-10	5166-5170	does	abstract[244]	new[244]	_	_
34-11	5171-5174	not	abstract[244]	new[244]	_	_
34-12	5175-5181	permit	abstract[244]	new[244]	_	_
34-13	5182-5184	to	abstract[244]	new[244]	_	_
34-14	5185-5194	determine	abstract[244]	new[244]	_	_
34-15	5195-5196	a	abstract[244]|abstract[247]	new[244]|new[247]	_	_
34-16	5197-5202	cause	abstract[244]|abstract|abstract[247]	new[244]|new|new[247]	_	_
34-17	5203-5206	and	abstract[244]|abstract[247]	new[244]|new[247]	_	_
34-18	5207-5213	effect	abstract[244]|abstract|abstract[247]	new[244]|new|new[247]	_	_
34-19	5214-5226	relationship	abstract[244]|abstract[247]	new[244]|new[247]	_	_
34-20	5227-5234	between	abstract[244]|abstract[247]	new[244]|new[247]	_	_
34-21	5235-5242	spatial	abstract[244]|abstract[247]|abstract[248]	new[244]|new[247]|giv[248]	_	_
34-22	5243-5255	distribution	abstract[244]|abstract[247]|abstract[248]	new[244]|new[247]|giv[248]	_	_
34-23	5256-5258	of	abstract[244]|abstract[247]|abstract[248]	new[244]|new[247]|giv[248]	_	_
34-24	5259-5267	pressure	abstract[244]|abstract[247]|abstract[248]|abstract|abstract[251]	new[244]|new[247]|giv[248]|giv|giv[251]	_	_
34-25	5268-5272	pain	abstract[244]|abstract[247]|abstract[248]|abstract|abstract[251]	new[244]|new[247]|giv[248]|giv|giv[251]	coref	35-11
34-26	5273-5284	sensitivity	abstract[244]|abstract[247]|abstract[248]|abstract[251]	new[244]|new[247]|giv[248]|giv[251]	_	_
34-27	5285-5288	and	abstract[244]|abstract[247]	new[244]|new[247]	_	_
34-28	5289-5292	the	abstract[244]|abstract[247]|event[252]	new[244]|new[247]|new[252]	_	_
34-29	5293-5304	development	abstract[244]|abstract[247]|event[252]	new[244]|new[247]|new[252]	_	_
34-30	5305-5307	or	abstract[244]|abstract[247]	new[244]|new[247]	_	_
34-31	5308-5319	maintenance	abstract[244]|abstract[247]|abstract[253]	new[244]|new[247]|new[253]	_	_
34-32	5320-5322	of	abstract[244]|abstract[247]|abstract[253]	new[244]|new[247]|new[253]	_	_
34-33	5323-5325	CH	abstract[244]|abstract[247]|abstract[253]|abstract	new[244]|new[247]|new[253]|giv	coref	35-22
34-34	5326-5327	.	_	_	_	_

#Text=However , the fact that headache-free control subjects showed heterogeneous pain maps suggests that the anterior-to-posterior gradient observed in men with CH is related to the presence of pain .
35-1	5328-5335	However	_	_	_	_
35-2	5336-5337	,	_	_	_	_
35-3	5338-5341	the	abstract[255]	new[255]	_	_
35-4	5342-5346	fact	abstract[255]	new[255]	_	_
35-5	5347-5351	that	abstract[255]	new[255]	_	_
35-6	5352-5365	headache-free	abstract[255]|abstract[256]	new[255]|new[256]	_	_
35-7	5366-5373	control	abstract[255]|abstract[256]	new[255]|new[256]	_	_
35-8	5374-5382	subjects	abstract[255]|abstract[256]	new[255]|new[256]	_	_
35-9	5383-5389	showed	abstract[255]	new[255]	_	_
35-10	5390-5403	heterogeneous	abstract[255]|abstract[258]	new[255]|giv[258]	_	_
35-11	5404-5408	pain	abstract[255]|abstract|abstract[258]	new[255]|giv|giv[258]	coref	35-29
35-12	5409-5413	maps	abstract[255]|abstract[258]	new[255]|giv[258]	_	_
35-13	5414-5422	suggests	_	_	_	_
35-14	5423-5427	that	_	_	_	_
35-15	5428-5431	the	abstract[259]	giv[259]	_	_
35-16	5432-5453	anterior-to-posterior	abstract[259]	giv[259]	_	_
35-17	5454-5462	gradient	abstract[259]	giv[259]	_	_
35-18	5463-5471	observed	abstract[259]	giv[259]	_	_
35-19	5472-5474	in	abstract[259]	giv[259]	_	_
35-20	5475-5478	men	abstract[259]|person[260]	giv[259]|giv[260]	_	_
35-21	5479-5483	with	abstract[259]|person[260]	giv[259]|giv[260]	_	_
35-22	5484-5486	CH	abstract[259]|person[260]|abstract	giv[259]|giv[260]|giv	coref	38-31
35-23	5487-5489	is	_	_	_	_
35-24	5490-5497	related	_	_	_	_
35-25	5498-5500	to	_	_	_	_
35-26	5501-5504	the	abstract[262]	new[262]	_	_
35-27	5505-5513	presence	abstract[262]	new[262]	_	_
35-28	5514-5516	of	abstract[262]	new[262]	_	_
35-29	5517-5521	pain	abstract[262]|abstract	new[262]|giv	coref	38-14
35-30	5522-5523	.	_	_	_	_

#Text=Longitudinal studies are needed to clarify this hypothesis .
36-1	5524-5536	Longitudinal	abstract[264]	giv[264]	coref	38-20[275_264]
36-2	5537-5544	studies	abstract[264]	giv[264]	_	_
36-3	5545-5548	are	_	_	_	_
36-4	5549-5555	needed	_	_	_	_
36-5	5556-5558	to	_	_	_	_
36-6	5559-5566	clarify	_	_	_	_
36-7	5567-5571	this	abstract[265]	new[265]	_	_
36-8	5572-5582	hypothesis	abstract[265]	new[265]	_	_
36-9	5583-5584	.	_	_	_	_

#Text=Finally , we only assessed static outcomes of nociception , i.e. , PPT .
37-1	5585-5592	Finally	_	_	_	_
37-2	5593-5594	,	_	_	_	_
37-3	5595-5597	we	person	giv	_	_
37-4	5598-5602	only	_	_	_	_
37-5	5603-5611	assessed	_	_	_	_
37-6	5612-5618	static	abstract[267]	new[267]	appos	37-11[269_267]
37-7	5619-5627	outcomes	abstract[267]	new[267]	_	_
37-8	5628-5630	of	abstract[267]	new[267]	_	_
37-9	5631-5642	nociception	abstract[267]|abstract	new[267]|new	_	_
37-10	5643-5644	,	_	_	_	_
37-11	5645-5649	i.e.	abstract[269]	giv[269]	coref	38-3[270_269]
37-12	5650-5651	,	abstract[269]	giv[269]	_	_
37-13	5652-5655	PPT	abstract[269]	giv[269]	_	_
37-14	5656-5657	.	_	_	_	_

#Text=Thus , dynamic outcomes such as temporal summation , wind-up , or conditioned pain modulation should be used in future studies to further characterize the presence of central sensitization in CH .
38-1	5658-5662	Thus	_	_	_	_
38-2	5663-5664	,	_	_	_	_
38-3	5665-5672	dynamic	abstract[270]	giv[270]	_	_
38-4	5673-5681	outcomes	abstract[270]	giv[270]	_	_
38-5	5682-5686	such	abstract[270]	giv[270]	_	_
38-6	5687-5689	as	abstract[270]	giv[270]	_	_
38-7	5690-5698	temporal	abstract[270]|abstract[271]	giv[270]|new[271]	_	_
38-8	5699-5708	summation	abstract[270]|abstract[271]	giv[270]|new[271]	_	_
38-9	5709-5710	,	abstract[270]	giv[270]	_	_
38-10	5711-5718	wind-up	abstract[270]|event	giv[270]|new	_	_
38-11	5719-5720	,	abstract[270]	giv[270]	_	_
38-12	5721-5723	or	abstract[270]	giv[270]	_	_
38-13	5724-5735	conditioned	abstract[270]|abstract[274]	giv[270]|new[274]	_	_
38-14	5736-5740	pain	abstract[270]|abstract|abstract[274]	giv[270]|giv|new[274]	_	_
38-15	5741-5751	modulation	abstract[270]|abstract[274]	giv[270]|new[274]	_	_
38-16	5752-5758	should	_	_	_	_
38-17	5759-5761	be	_	_	_	_
38-18	5762-5766	used	_	_	_	_
38-19	5767-5769	in	_	_	_	_
38-20	5770-5776	future	abstract[275]	giv[275]	_	_
38-21	5777-5784	studies	abstract[275]	giv[275]	_	_
38-22	5785-5787	to	_	_	_	_
38-23	5788-5795	further	_	_	_	_
38-24	5796-5808	characterize	_	_	_	_
38-25	5809-5812	the	abstract[276]	new[276]	_	_
38-26	5813-5821	presence	abstract[276]	new[276]	_	_
38-27	5822-5824	of	abstract[276]	new[276]	_	_
38-28	5825-5832	central	abstract[276]|abstract[277]	new[276]|giv[277]	_	_
38-29	5833-5846	sensitization	abstract[276]|abstract[277]	new[276]|giv[277]	_	_
38-30	5847-5849	in	abstract[276]|abstract[277]	new[276]|giv[277]	_	_
38-31	5850-5852	CH	abstract[276]|abstract[277]|abstract	new[276]|giv[277]|giv	_	_
38-32	5853-5854	.	_	_	_	_
